HOME ABOUT US SERVICES RESEARCH EQUITY DERIVATIVES IPO INTERNET TRADING FTP CONTACT US
  
SENSEX 4.10 0.02%
24211.00
 
NIFTY 47.01 0.06%
77616.40
 
Nasdaq -408.43 -1.55%
25873.18
 
Nikkei 225 -1315.00 -1.92%
67242.73
 
FTSE 100 1.00 0.01%
10498.30
 
YOU ARE ON
Equity
Equity Analysis
Price
Gainers & Losers
Out & Under Performers
Only Buyers & Sellers
Advances & Declines
New Highs & Lows
Weightage
5 Day's Up & Down
Historical Returns
Volume
Analysis
News Analysis
Corporate Action
Corporate Info
Other Market
 
Bacil Pharma Ltd.
 
Source DateBoard Meeting DateDetails
03-Jul-2026 09-Jul-2026 Inter alia, to consider and approve the following:- 1. The proposal for raising funds by way of a Rights Issue of equity shares to the eligible equity shareholders of the Company for an aggregate amount of up to Rs.50,00,00,000 (Rupees Fifty Crores Only), in accordance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws, subject to such statutory and regulatory approvals as may be required. 2. The proposal for increase in the Authorised Share Capital of the Company, if required, to facilitate the proposed Rights Issue and to ensure adequate headroom for issuance of equity shares pursuant thereto. 3. Consequent alteration of the Capital Clause of the Memorandum of Association of the Company and other related documents, if required, subject to the approval of the Board and the shareholders of the Company, as applicable. 4. To determine and approve the detailed terms and conditions of the Rights Issue, including but not limited to the issue size, rights entitlement ratio, issue price, record date, rights issue schedule, appointment of intermediaries, draft Letter of Offer and such other matters incidental or connected therewith. 5. Discussion on Appointment and Resignation of Directors. 6. Any other matter incidental or connected with the proposed Rights Issue and increase in the Authorised Share Capital
23-Jun-2026 26-Jun-2026 Inter alia, to consider and evaluate proposals for raising funds by the Company through one or more permissible modes, subject to such statutory and regulatory approvals as may be required, including but not limited to: 1.. Preferential Issue (including preferential allotment of equity shares and/or convertible securities); 2. Rights Issue; Any other permissible mode or combination thereof, as may be considered appropriate by the Board, in accordance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws. The Board may also consider and transit any other business, if any, which may be placed before the Board with the permission of the Chairman
11-May-2026 22-May-2026 Audited Results
05-Feb-2026 13-Feb-2026 Quarterly Results
06-Nov-2025 13-Nov-2025 Quarterly Results
02-Sep-2025 05-Sep-2025 Inter alia, To discuss and approve the following matters: ? Discussion on Notice for 38th Annual General Meeting for the Company. ? Discussion on Director Report of the Company for the Financial Year 2024-2025. ? Discussion to Fix Date, Place and Timing of 38th Annual General Meeting of the Company ? Discussion on matter related to Loan to Equity shares of the Company. ? Any other business with the permission of Chairperson.
19-Aug-2025 25-Aug-2025 Inter alia, to consider and approve:- 1. Discussion on Appointment of M/s Sarang Shivajirao Chavan& Associate as a Statutory Auditor of the Company; 2. Discussion on Appointment of New Director. 3. Any other business with the permission of Chairperson.
05-Aug-2025 12-Aug-2025 Quarterly Results
11-Jul-2025 16-Jul-2025 Inter alia, to consider and approve:- 1. To consider and discuss the appointment of a new Executive Director and Chief Financial Officer (CFO) of the Company; 2. To consider and discuss the resignation of the present Chief Financial Officer (CFO) of the Company. 3. Any other business with the permission of chair.
19-May-2025 26-May-2025 Audited Results
13-Jan-2025 21-Jan-2025 Quarterly Results
16-Oct-2024 23-Oct-2024 Quarterly Results
10-Oct-2024 15-Oct-2024 Inter alia, to discuss, consider and approve agendas as follows: - 1. To discuss and take final decision on acquisition of equity shares of M/s CNX Corporation Limited ("CCL"), from the existing shareholders of "CCL", on which the Board of Directors has given their initial approval in its meeting held on 27th September 2024, the board will decide the no. of shares to be acquire, price of acquisition, mode of payment consideration etc. and other terms and conditions for acquisition of Eq. Shares of "CCL" subject to the due diligence and valuation reports in its meeting. 2. To discuss and approve the proposal for offer, Issue, and allot Equity Shares of the company on a Preferential Basis to the shareholders of M/s CNX Corporation Limited ("CCL") for consideration other than cash (share swap), which will be determined in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations"), for a consideration other than cash (share swap)(for discharge of entire purchase consideration) to the shareholders of M/s CNX Corporation Limited ("CCL"), on such terms and conditions which will be approved by board in this meeting, subject to the shareholders approval in ensuing general meeting of the company. 3. To discuss and approve the proposal for fund raising by offer, Issue, and allot Equity Shares
23-Sep-2024 27-Sep-2024 Increase in Authorised Capital
07-Aug-2024 14-Aug-2024 Quarterly Results
14-May-2024 21-May-2024 Audited Results
05-Feb-2024 13-Feb-2024 Quarterly Results
02-Nov-2023 10-Nov-2023 Quarterly Results
07-Aug-2023 14-Aug-2023 Quarterly Results
08-May-2023 16-May-2023 Audited Results
Page 1 of 6
Prev || Next
 
ADINATH STOCK BROKING PVT LTD  :   SEBI REGISTRATION NUMBERS : Bombay Stock Exchange(BSE): CASH -INZ000204337 & DERIVATIVE -INZ000204337 Member ID-3175 National Stock Exchange(NSE): CASH- INZ000204337 & DERIVATIVES -INZ000204337 Member ID-12805 MCX-SX Stock Exchange(MCX-SX): Currency Derivative : INZ000204337 Member ID-44400 United Stock Exchange(USE): Currency Derivative: Central Depository Services Ltd(CDSL)- IN -DP-452/2008 DP ID 12055200
ATTENTION INVESTORS :   "Prevent unauthorised transactions in your Broking & demat account--> Update your mobile numbers/email IDs with your stock brokers & depository participate. Receive information of your transactions directly from Exchange & CDSL on your mobile/email at the end of the day......................Issued in the interest of Investors"
ATTENTION INVESTORS :   "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
ATTENTION INVESTORS :   "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
ATTENTION INVESTORS :   1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 3. Pay 20% upfront margin of the transaction value to trade in cash market segment 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. "Issued in the interest of Investors"
| Disclaimer | Privacy Policy | Feedback | Terms and Conditions | Careers | Investor Grievances | Download | Investor Protection | SCORES | Site Map
Investor Charter - DP | Investor Charter - Stock Broker | e-voting | Investor Education | Client Collateral Details | NSDL eVoting | Advisory for investors
Useful links: NSE | BSE | MCX-SX | CDSL | SEBI | MCX | NCDEX | FMC | Smart ODR
SEBI Registration No.INZ000042629
Copyright © 2011 Adinath Stock Broking Pvt Ltd                             Designed, Developed & Content Powered By ●●● Accord Fintech Pvt.Ltd.